Literature DB >> 11494314

The role of chemoattraction in cancer metastases.

M A Moore1.   

Abstract

It has long been unclear as to why particular cancers preferentially metastasize to certain sites. The possibilities usually discussed involve differential survival and proliferation at these sites, or selective trapping with or without preferential homing. A recent report by Muller et al.(1) provides evidence for preferential homing of breast cancer to metastatic sites. The findings indicate that the chemokine receptors CXCR4 and CCR7 are found on breast cancer cells and their ligands are highly expressed at sites associated with breast cancer metastases. This results in chemotaxis, or directed migration of tumor cells from their primary site via the circulation to the preferential sites of metastases. The evidence for this model and its significance are reviewed here. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494314     DOI: 10.1002/bies.1095

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  34 in total

Review 1.  Cellular and molecular processes leading to embryo formation in sponges: evidences for high conservation of processes throughout animal evolution.

Authors:  Alexander V Ereskovsky; Emmanuelle Renard; Carole Borchiellini
Journal:  Dev Genes Evol       Date:  2012-04-29       Impact factor: 0.900

2.  SEOM guidelines for the treatment of bone metastases from solid tumours.

Authors:  Javier Cassinello Espinosa; Aránzazu González Del Alba Baamonde; Fernando Rivera Herrero; Esther Holgado Martín
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

3.  Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

Authors:  Zeng B Zhu; Angel A Rivera; Sharmila K Makhija; Baogen Lu; Minghui Wang; Miiru Izumi; Robert J Cerfolio; Mariam A Stoff-Khalili; Fen Zhou; Koichi Takayama; Gene P Siegal; David T Curiel
Journal:  Lung Cancer       Date:  2006-11-17       Impact factor: 5.705

4.  Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+  DLBCL.

Authors:  Liang Wu; Barbro Ehlin-Henriksson; Xiaoying Zhou; Hong Zhu; Ingemar Ernberg; Lorand L Kis; George Klein
Journal:  Immunology       Date:  2017-08-11       Impact factor: 7.397

5.  C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.

Authors:  Lingyun Zhang; Yuee Teng; Ye Zhang; Jing Liu; Ling Xu; Jinglei Qu; Kezuo Hou; Xianghong Yang; Yunpeng Liu; Xiujuan Qu
Journal:  Oncol Lett       Date:  2011-11-16       Impact factor: 2.967

6.  CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.

Authors:  Crystal Johnson-Holiday; Rajesh Singh; Erica Johnson; Shailesh Singh; Cecil R Stockard; William E Grizzle; James W Lillard
Journal:  Int J Oncol       Date:  2011-02-23       Impact factor: 5.650

7.  Characterization of Lewis lung clonal variants in a model of syngeneic pulmonary murine metastases.

Authors:  Bill T Storey; H Keith Pittman; Joseph F Christian; Carl E Haisch; Kathryn M Verbanac
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism.

Authors:  Whitney L Jamieson; Saori Shimizu; Julia A D'Ambrosio; Olimpia Meucci; Alessandro Fatatis
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

10.  Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells.

Authors:  Daisuke Uchida; Tomitaro Onoue; Nasima-Mila Begum; Nobuyuki Kuribayashi; Yoshifumi Tomizuka; Tetsuya Tamatani; Hirokazu Nagai; Youji Miyamoto
Journal:  Mol Cancer       Date:  2009-08-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.